The (PERFUSE) study evaluating the persistence, effectiveness & safety of Flixabi in 569 patients with Crohn’s disease and 168 patients with ulcerative colitis at specialist sites across France
For CD & UC, the results showed persistence (89% & 78.5%) at 12mos. who were naïve to infliximab; 94% & 92.8% in the infliximab reference group; 100% & 100% in the infliximab multi-switch group, disease activity among infliximab naive patients declined from baseline to 12mos.
The proportions of patients in remission at baseline, 6 & 12mos. remained unchanged in the UC cohort, and were comparable or higher in the CD cohort, no immunogenicity or safety signals were seen. Infliximab biosimilar was safe & efficacious for IBD
Ref: Hcplive | Image: Biogen
Related News:- Eisai and Biogen Report the US FDA’s Acceptance of sBLA and Granted Priority Review for Leqembi (lecanemab-irmb) to Treat Alzheimer’s Disease
